Syngene International

727.00
-2.15
(-0.29%)
ann
There are new updates from the company9 hours ago
Viewcross
right
Market Cap
29,264.44 Cr
EPS
12.71
PE Ratio
61.48
Dividend Yield
0.17 %
Industry
Healthcare
52 Week High
960.60
52 Week Low
607.65
PB Ratio
6.68
Debt to Equity
0.17
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from10 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+60.00 %
+60.00 %
Hold
Hold+10.00 %
+10.00 %
Sell
Sell+30.00 %
+30.00 %
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
727.00
#1 29,264.44
#3 61.48
#1 3,579.20
#4 9.66
#1 510
#4 17.58
55.64
570.15
13,681.01
36.09
2,665.90
12.77
337
11.03
53.38
126.32
2,754.71
-
32.80
#1 49.09
-105
6.46
54.30
972.20
2,160.50
35.92
322.30
0.22
41
112.87
49.57
87.31
205.54
-
769.70
-22.39
-59
17.26
57.73
8.67
128.26
-
67.20
-65.97
-120
#1 2,371.43
52.07
42.00
66.48
94.48
40.30
8.04
-1
120.00
49.00
16.00
26.30
#1 33.09
80.00
-3.26
2
-80.00
37.86
24.20
15.30
-
9.80
40.00
-9
-380.00
42.85

Automatic Screeners on ScanX

Growth Rate
Revenue Growth
9.66 %
Net Income Growth
9.82 %
Cash Flow Change
26.55 %
ROE
-6.70 %
ROCE
-3.05 %
EBITDA Margin (Avg.)
0.23 %

Quarterly Financial Results

Quarterly Financials
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
399
426
425
437
484
555
441
557
539
628
437
533
602
712
607
623
654
773
660
784
803
1,017
832
932
883
933
840
908
962
Expenses
262
280
297
292
327
374
300
325
366
403
297
364
408
443
430
464
438
508
472
552
555
680
596
663
626
600
620
646
660
EBITDA
138
146
128
145
158
181
142
231
174
225
140
170
193
269
177
160
216
265
188
232
248
337
236
268
257
333
220
261
302
Operating Profit %
33 %
32 %
27 %
30 %
30 %
30 %
29 %
30 %
30 %
34 %
30 %
30 %
30 %
33 %
28 %
24 %
32 %
33 %
27 %
28 %
29 %
32 %
26 %
27 %
27 %
35 %
22 %
27 %
30 %
Depreciation
35
34
37
40
43
44
47
53
57
62
66
69
70
70
75
76
79
80
86
90
95
96
102
105
108
111
107
111
109
Interest
5
7
8
8
8
8
7
8
10
9
7
7
7
7
8
1
9
6
9
12
14
10
11
13
11
13
12
13
12
Profit Before Tax
98
104
83
97
107
129
87
170
107
153
66
94
117
192
95
82
128
179
93
130
140
231
123
151
138
209
101
137
181
Tax
16
20
17
19
20
29
15
42
15
33
8
10
14
32
17
16
24
31
19
28
30
52
30
34
27
20
26
31
50
Net Profit
82
85
66
78
87
100
72
128
92
120
58
84
102
161
77
67
104
148
74
102
110
179
93
117
112
189
76
106
131
EPS in ₹
4.14
4.27
3.34
3.96
2.20
2.53
1.82
3.23
2.32
3.03
1.47
2.12
2.57
4.04
1.91
1.64
2.57
3.71
1.85
2.55
2.74
4.36
2.33
2.90
2.78
4.70
1.89
2.64
3.27

Balance Sheet

Balance Sheet
2018
2019
2020
2021
2022
2023
2024
Total Assets
3,189
3,704
4,163
4,883
5,564
5,831
6,152
Fixed Assets
1,030
1,377
2,020
2,201
2,393
2,667
2,850
Current Assets
1,720
1,764
1,613
1,807
2,206
2,425
1,959
Capital Work in Progress
155
274
234
237
346
177
838
Investments
158
716
776
702
1,034
919
548
Other Assets
1,846
1,337
1,133
1,743
1,791
2,069
1,916
Total Liabilities
3,189
3,704
4,163
4,883
5,564
5,831
6,152
Current Liabilities
784
1,129
1,539
1,133
1,229
1,188
1,144
Non Current Liabilities
685
607
448
929
1,037
1,025
750
Total Equity
1,720
1,968
2,176
2,821
3,298
3,618
4,258
Reserve & Surplus
1,520
1,768
1,776
2,421
2,897
3,217
3,856
Share Capital
200
200
400
400
401
401
402

Cash Flow

Cash Flow
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
18
-88
28
130
-62
-172
-4
Investing Activities
-349
-646
-424
-629
-611
-653
-494
Operating Activities
446
630
677
701
581
824
1,042
Financing Activities
-79
-72
-226
58
-31
-343
-552

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
70.58 %
70.43 %
70.42 %
70.41 %
70.41 %
70.29 %
64.86 %
64.86 %
54.88 %
54.80 %
54.79 %
54.79 %
54.79 %
54.72 %
54.72 %
52.74 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.02 %
0.02 %
0.00 %
0.00 %
0.00 %
20.92 %
20.63 %
20.72 %
20.64 %
DIIs
4.02 %
3.81 %
4.03 %
3.64 %
3.26 %
2.79 %
4.96 %
7.04 %
10.73 %
11.20 %
9.94 %
13.08 %
15.80 %
16.80 %
17.48 %
19.53 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
8.05 %
8.29 %
8.46 %
9.20 %
9.22 %
9.02 %
8.81 %
8.57 %
8.39 %
8.10 %
7.53 %
7.24 %
6.45 %
6.08 %
5.45 %
5.59 %
Others
17.35 %
17.46 %
17.09 %
16.76 %
17.11 %
17.90 %
21.36 %
19.52 %
25.98 %
25.90 %
27.73 %
24.89 %
2.03 %
1.77 %
1.62 %
1.50 %
No of Share Holders
1,15,632
1,26,395
1,36,749
1,37,892
1,33,610
1,28,278
1,34,334
1,27,964
1,24,014
1,25,455
1,25,992
1,21,880
1,15,850
1,20,018
1,07,338
1,28,806

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 1 1 0.5 0.00 0.00 1 1.25 1.25 0.00
Dividend Yield (%) 0.00 0.33 0.34 0.21 0.00 0.00 0.17 0.18 0.17 0.00

Corporate Action

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation9 hours ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20186 days ago
Board Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results For The Quarter And Year Ending March 31 2025; And To Consider The Recommendation Of Final Dividend If Any.10 days ago
Grant Of Performance Share Units Under Syngene Long-Term Incentive Performance Share Plan 2023 (Plan)Apr 01, 2025
Grant Of Performance Share Units Under Syngene Long-Term Incentive Performance Share Plan 2023 (Plan)Apr 01, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 01, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 01, 2025
Intimation Of An Update On The Tax Litigations.Mar 29, 2025
Reminder - Communication To Shareholders For Claiming Unclaimed Dividends.Mar 28, 2025
Intimation Of Disclosure On Receipt Of Order From The Income Tax Department.Mar 28, 2025
Closure of Trading WindowMar 27, 2025
Intimation Of Additional Disclosure On Update On The Tax LitigationsMar 27, 2025
Intimation Of Additional Disclosure On Receipt Of Orders From The Income Tax DepartmentMar 27, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Receipt Of Order From Income Tax DepartmentMar 26, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMar 24, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Receipt Of Order From Income Tax DepartmentMar 24, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 23, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 23, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 18, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMar 12, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMar 10, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 10, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 07, 2025
Grant Of Performance Share Units Under Syngene Long-Term Incentive Performance Share Plan 2023 (Plan)Mar 01, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 27, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 27, 2025
Update On Pre-Approval And Cgmp Inspection By United States Food & Drug Administration (USFDA).Feb 21, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Feb 15, 2025
Intimation Of Cancellation Of Meetings With Analysts/Institutional InvestorsFeb 10, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 10, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 10, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 05, 2025
Grant Of Performance Share Units Under Syngene Long-Term Incentive Performance Share Plan 2023 (Plan)Feb 01, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Jan 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 28, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Jan 27, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 23, 2025
Intimation Of Amendment Of Code Of Practices And Procedures For Fair Disclosure Of Unpublished Price Sensitive Information (UPSI) Of The Company.Jan 23, 2025
Intimation Of Change In Key Managerial Personnel (KMP) To Determine Materiality Of An Event Or InformationJan 23, 2025
Integrated Filing (Financial)Jan 23, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJan 23, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 23, 2025
Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024.Jan 23, 2025
Board Meeting Outcome for Outcome Of The Board Meeting - January 23 2025Jan 23, 2025
Revised Intimation Of Conference Call For Analysts And InvestorsJan 17, 2025

Technical Indicators

RSI(14)
Neutral
55.64
ATR(14)
Less Volatile
23.61
STOCH(9,6)
Neutral
54.57
STOCH RSI(14)
Neutral
56.78
MACD(12,26)
Bullish
1.90
ADX(14)
Weak Trend
20.61
UO(9)
Bearish
55.09
ROC(12)
Uptrend And Accelerating
1.04
WillR(14)
Neutral
-30.61

About Syngene International

Syngene International Limited is an integrated research, development, and manufacturing services company headquartered in India. It serves global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. The company operates across four business divisions: Discovery Services, Development Services, Manufacturing Services, and Dedicated Centers. With approximately 6000 scientists, Syngene has facilities spanning 2.2 million sq. ft. in Bangalore, Hyderabad, and Mangalore. It provides end-to-end services within Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO). Syngene offers various platforms and services including drug discovery, development capabilities, custom synthesis, process R&D, cGMP manufacturing, and clinical development services. The company has partnerships and collaborations with multiple global pharmaceutical and healthcare companies, expanding its research and manufacturing capabilities over the years.
Listing Date
11 Aug, 2015(9 Years, 39 days)
Chairperson NameKiran Mazumdar Shaw